Heart healthBrain & nervous system

Treatment options for HATTR amyloidosis

An overview of TTR stabilizers and gene-silencing therapies for treating hereditary transthyretin (hATTR) amyloidosis.


LearnHeartAmyloidosisTreatment options for HATTR amyloidosis
  • Treatment options for hATTR amyloidosis
  • Managing symptoms and complications

Hereditary transthyretin amyloidosis (hATTR amyloidosis) is a rare genetic disorder that causes a buildup of abnormal proteins called transthyretin (TTR) proteins.

TTR proteins are "transport proteins"—proteins that help move hormones and vitamins into cells. Most TTR proteins are made in the liver, while small amounts are produced in the brain.

When a person has hATTR amyloidosis, genetic mutations cause the body to produce misfolded TTR proteins. Misfolded TTR proteins are misshapen and do not function correctly. As more misfolded TTR proteins accumulate, they form deposits that can damage the organs and tissues where they are located. This is called amyloidosis.

People with hATTR amyloidosis experience nerve damage, stiffening and thickening of the heart muscle, gastrointestinal problems, kidney disease, and other complications. Symptoms and complications become more severe over time, especially when the disorder is untreated.

For many years, liver transplants were considered the best treatment option—because most TTR was made in the liver, receiving a transplanted liver would reduce the production of the misfolding TTR and help prevent further damage to the body. Liver transplants are most successful when performed in young patients in the early stages of the disease. Liver transplants also appear to be more effective for cases caused by specific gene mutations. Heart transplants are also used in cases where the disease has damaged the heart.

Over the past decade, new treatments have become available and liver transplants have become less common. While there are no therapies that can cure hATTR amyloidosis, there are therapies that can help people manage this condition and slow the progression of the disease.

Treatment options for hATTR amyloidosis

Treatments for hATTR amyloidosis fall into two main categories— therapies that prevent the TTR protein from misfolding and therapies that reduce the production of TTR protein. Keep in mind that these are simplified explanations of complex mechanisms:

TTR stabilizers

TTR stabilizers are medications that attach to TTR proteins, stabilize the proteins, and prevent misfolding. This prevents the formation of amyloid deposits and helps slow the progression of the disease. Some medications are approved for the treatment of hATTR amyloidosis, and others are prescribed off-label. Off-label means that a drug has been approved for other conditions, but it has been shown to benefit people with a different condition.

Gene-silencing therapies

The body has a built-in defense mechanism that helps clear up gene mutations and regulate protein production. It is called RNA interference. Gene-silencing therapies are drugs that mimic this process. Gene-silencing therapies for hATTR work by interfering with the production of misfolding TRR proteins.

Research into hATTR is ongoing, and new therapies are under development.

Managing symptoms and complications

Managing symptoms and complications are also an important part of treatment for hATTR. It can include medications to manage nerve pain and discomfort, medications and therapies to treat cardiac complications like heart failure, and therapies to help with gastrointestinal symptoms. Good nutrition and overall health should also be a focus of treatment.

Hereditary ATTR is a different experience for different people. Treatment for hATTR should be individualized to a person's specific symptoms and needs. Your best source of information about treatment options for hATTR will be your healthcare providers.

Sources: American Heart Association: Answers by h... + 16
  1. American Heart Association: Answers by heart. What is hATTR amyloidosis?
  2. Fiore Manganelli, Gian Maria Fabrizi, et al. Hereditary transthyretin amyloidosis overview. Neurological Science, 2020. Vol. 43, Suppl. 2).
  3. MedlinePlus Genetics. TTR gene.
  4. ScienceDirect. Transport Protein.
  5. Loris Poli, Beatrice Labella, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Frontiers in Neurology, 2023. Vol. 14.
  6. Yale Medicine. Amyloidosis.
  7. ScienceDirect. Protein Misfolding.
  8. Robert O. Holmes, Jr. Amyloidosis. Medscape. March 27, 2023.
  9. Morie A. Gertz. Hereditary Amyloidosis: 5 Things to Know. Medscape Oncology. April 29, 2024.
  10. Jefferson R. Roberts. Transthyretin-Related Amyloidosis. Medscape. March 27, 2024.
  11. Cedars Sinai. ATTR Amyloidosis.
  12. Maria Teresa Mallus and Vittoria Rizzello. Treatment of amyloidosis: present and future. European Heart Journal Supplements, 2023. Vol 25, No. Suppl. B.
  13. Jan M. Griffin, Julie L. Rosenthal, et al. ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology, 2021. Vol. 3, No. 4.
  14. Cleveland Clinic. Transthyretin Amyloidosis (ATTR-CM).
  15. Agency for Healthcare Research and Quality. Off-Label Drugs: What You Need to Know.
  16. Giles Campion. Gene silencing: A potential new treatment for rare disease. PharmaiQ. June 28, 2022.
  17. National Organization for Rare Disorders. Amyloidosis.
Written by Jameson Kowalczyk.
Medically reviewed by Ann Wendling, MD, MPH.December, 2024
Updated onAugust, 2026
Written by Jameson Kowalczyk.
Medically reviewed by Ann Wendling, MD, MPH.December, 2024
Updated onAugust, 2026
  • Treatment options for hATTR amyloidosis
  • Managing symptoms and complications
AskMDAskMD

Concerned about your heart health?

Get instant answers from our AI health assistant

Ask Now

Recommended for you

Transthyretin amyloid cardiomyopathy is a condition that is caused by a buildup of abnormal protein deposits in the heart.

Living with and treating ATTR amyloidosis
Video

A look at the early symptoms of ATTR peripheral neuropathy and ATTR cardiomyopathy.

What are the early symptoms of ATTR?
Article

Understand the facts about this congenital heart condition.

What to know about Tetralogy of Fallot
Article

Susheel Kodali, MD, talks through how CT-guided planning and other procedural advancements are improving TAVR outcomes.

Dx dialogues: CT-guided planning and procedural advancements in TAVR
Video

Find out why cynical people may be more likely to develop dementia.

How your outlook may affect your brain
Article
AskMDHow can I be more consistent?
AskMD by Sharecare LogoAskMD by Sharecare Logo
Privacy policyConsumer health data privacyTerms of use
Cookie policyYour privacy choices

© 2026 Sharecare, Inc.

ask-mdask-md
AskMD by Sharecare LogoAskMD by Sharecare Logo
Privacy policyConsumer health data privacyTerms of use
Cookie policyYour privacy choices

© 2026 Sharecare, Inc.